Suppr超能文献

一项关于疑似泌乳素微腺瘤患者临床结局和体积变化趋势的多中心研究。

A multicenter study of clinical outcomes and volumetric trends in suspected microprolactinomas.

机构信息

Department of Neurosurgery, Computational Neurosciences Outcomes Center, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Street, BTM 4, Boston, MA, 02115, USA.

Division of Neurosurgery, Department of Surgery, VA Boston Healthcare System, Boston, United States.

出版信息

Neurosurg Rev. 2024 Sep 28;47(1):703. doi: 10.1007/s10143-024-02951-7.

Abstract

The diagnosis of pituitary microprolactinomas is often obscured by relatively low levels of elevated prolactin compared to macroprolactinomas. This may lead to varying patterns of medical therapy versus observation. We sought to correlate prolactin levels in suspected microprolactinomas with tumor volumes and clinical outcomes. This was a multicenter retrospective study of patients with pituitary microadenomas with baseline prolactin levels > 18ng/ml for males and > 30ng/ml for females. A linear-mixed model was used to depict changes in tumor volume over time. There were 65 patients with a mean tumor volume of 95.9mm and mean prolactin level of 59.4ng/ml. There were significantly higher prolactin levels in patients with tumors above the mean volume versus below (74.0 versus 53.4ng/ml, p = 0.027). 26 patients were observed, 31 were treated with anti-dopaminergic therapy, and 8 had surgery. There were significantly greater baseline prolactin levels for patients who were treated surgically (mean 86.4ng/ml) than those treated medically (mean 61.7 g/ml) or observed (mean 48.5ng/ml) (p = 0.02). Among the 26 patients who were surveilled, 13 patients demonstrated spontaneous tumor shrinkage, 12 remained stable, and 1 patient's tumor grew but was lost to follow-up. Linear mixed modeling demonstrated a statistically significant rate of tumor shrinkage over time of 3.67mm/year (p = 0.03). When analyzing patients who were observed versus those requiring surgery after initially being surveilled, there were significantly greater baseline PRL/volume ratios in surgical patients versus those observed (8.1 ng/ml/mm versus 2.4 ng/ml/mm, p = 0.025). Suspected microprolactinomas may demonstrate more convincingly elevated prolactin levels when measuring over 95.9mm. Tumors with baseline prolactin levels over 50ng/ml may be more inclined to undergo medical treatment. In tumors with levels below 50ng/ml, it may be reasonable to undergo surveillance as these tumors tend to spontaneously shrink over time. In tumors that are surveilled, an elevated baseline PRL/volume ratio of > 8 ng/ml/mm may be indicate serial tumor growth that may necessitate medical and/or surgical intervention.

摘要

垂体微腺瘤的诊断常因与大腺瘤相比,泌乳素水平升高幅度相对较低而受到影响。这可能导致不同的治疗模式,即观察与药物治疗。我们旨在将疑似微腺瘤患者的泌乳素水平与肿瘤体积和临床结果进行关联。这是一项多中心回顾性研究,纳入了基线泌乳素水平男性 > 18ng/ml 和女性 > 30ng/ml 的垂体微腺瘤患者。采用线性混合模型描绘肿瘤体积随时间的变化。共纳入 65 例平均肿瘤体积为 95.9mm 和平均泌乳素水平为 59.4ng/ml 的患者。肿瘤体积大于平均值的患者泌乳素水平显著高于体积小于平均值的患者(74.0 与 53.4ng/ml,p = 0.027)。26 例患者接受观察,31 例接受多巴胺能药物治疗,8 例接受手术治疗。手术治疗患者的基线泌乳素水平显著高于药物治疗(86.4ng/ml)和观察(48.5ng/ml)患者(p = 0.02)。在接受观察的 26 例患者中,13 例肿瘤自发缩小,12 例肿瘤稳定,1 例肿瘤增大但失访。线性混合模型显示,肿瘤随时间的平均缩小率为 3.67mm/年(p = 0.03)。在分析最初接受观察后需要手术或继续观察的患者时,手术治疗患者的基线 PRL/体积比值显著高于观察患者(8.1 ng/ml/mm 与 2.4 ng/ml/mm,p = 0.025)。当测量超过 95.9mm 时,疑似微腺瘤可能表现出更明显的泌乳素水平升高。基线泌乳素水平超过 50ng/ml 的肿瘤可能更倾向于接受药物治疗。对于基线泌乳素水平低于 50ng/ml 的肿瘤,进行观察可能是合理的,因为这些肿瘤随时间推移会自发缩小。在接受观察的肿瘤中,基线 PRL/体积比值> 8 ng/ml/mm 可能表明肿瘤存在连续生长,这可能需要进行药物和/或手术干预。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验